MoneyTV features bioengineering and stem cell topics this week

NewsGuard 100/100 Score

Bioengineering, extracting health products from waste tobacco, stem cells, unemployment, wind energy; this week on MoneyTV, hosted by anchor Donald Baillargeon. MoneyTV is the internationally syndicated television program all about money and what makes it happen (http://www.moneytv.net), featuring informative interviews with company CEOs, providing insights into their operations and outlooks for their futures.

Free information packages from the featured companies can be requested by sending an email to [email protected].

The television program can also be viewed online immediately at www.moneytv.net.

Featured companies on this week's program include:

ONE Bio Corporation (OTCBB: ONBI) CEO Marius Silvasan discussed the company's business model of bioengineering, utilizing green processes, combining high growth and margin Asian products with North American managerial expertise.

Cord Blood America, Inc. (OTCBB: CBAI) CEO Matthew Schissler talked about the late January opening of their Las Vegas facility and commented on recent stem cell news.

Brewer Investment Group Chief Market Analyst Jim Hyerczyk said the unemployment report would set Fed policy for the next six months.

iTokk, Inc. (OTCBB: IKTO) CEO Kevin Penstock updated recent progress the company has made.

Gazoo Energy Corporation (OTCBB: GAZU) CEO Chip Hackley introduced the company to MoneyTV.

RBC Wealth Management Senior VP Irwin Shapiro talked about high yield, tax free bond opportunities.

SOURCE: MoneyTV; ONE Bio Corporation; Cord Blood America, Inc.; Gazoo Energy Corporation; RBC Wealth Management; iTokk, Inc.; Brewer Investment Group

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Novel immunotherapy shows promise for high-risk sarcomas: HEROS 2.0 trial results published